These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 18463327)

  • 21. Ixabepilone: clinical role in metastatic breast cancer.
    Denduluri N; Swain S
    Clin Breast Cancer; 2011 Jun; 11(3):139-45. PubMed ID: 21665133
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Epothilones in breast cancer: review of clinical experience.
    Fornier MN
    Ann Oncol; 2007 Jul; 18 Suppl 5():v16-21. PubMed ID: 17656557
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The efficacy and safety of ixabepilone monotherapy in the treatment of breast and gynecologic malignancies.
    Gupta D; Mani S
    Expert Opin Drug Saf; 2009 Jan; 8(1):81-8. PubMed ID: 19236220
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development of novel chemotherapeutic agents to evade the mechanisms of multidrug resistance (MDR).
    Lee JJ; Swain SM
    Semin Oncol; 2005 Dec; 32(6 Suppl 7):S22-6. PubMed ID: 16360719
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ixabepilone for the treatment of breast cancer.
    Alvarez RH; Valero V; Hortobagyi GN
    Ann Med; 2011; 43(6):477-86. PubMed ID: 21585248
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lapatinib and ixabepilone for the treatment of metastatic breast cancer.
    Halterman PA
    Pharmacotherapy; 2008 Oct; 28(10):1255-66. PubMed ID: 18823221
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epothilones: clinical update and future directions.
    Donovan D; Vahdat LT
    Oncology (Williston Park); 2008 Apr; 22(4):408-16; discussion 416, 421, 424 passim. PubMed ID: 18472615
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ixabepilone plus capecitabine for breast cancer patients with an early metastatic relapse after adjuvant chemotherapy: two clinical trials.
    Fornier M
    Clin Breast Cancer; 2010 Oct; 10(5):352-8. PubMed ID: 20920979
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of ixabepilone in ER/PR/HER2-negative (triple-negative) breast cancer.
    Perez EA; Patel T; Moreno-Aspitia A
    Breast Cancer Res Treat; 2010 Jun; 121(2):261-71. PubMed ID: 20229176
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ixabepilone and other epothilones: microtubule-targeting agents for metastatic breast cancer.
    Morris PG; Fornier MN
    Clin Adv Hematol Oncol; 2009 Feb; 7(2):115-22. PubMed ID: 19367253
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of the pharmacokinetics of ixabepilone for the treatment of breast cancer.
    De Luca A; D'Alessio A; Maiello MR; Gallo M; Chicchinelli N; Pergameno M; Piccirilli MS; Normanno N
    Expert Opin Drug Metab Toxicol; 2015 Jul; 11(7):1177-85. PubMed ID: 26073581
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer.
    Thomas E; Tabernero J; Fornier M; Conté P; Fumoleau P; Lluch A; Vahdat LT; Bunnell CA; Burris HA; Viens P; Baselga J; Rivera E; Guarneri V; Poulart V; Klimovsky J; Lebwohl D; Martin M
    J Clin Oncol; 2007 Aug; 25(23):3399-406. PubMed ID: 17606975
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epothilones: a novel class of non-taxane microtubule-stabilizing agents.
    Altaha R; Fojo T; Reed E; Abraham J
    Curr Pharm Des; 2002; 8(19):1707-12. PubMed ID: 12171542
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Current combination chemotherapy regimens for metastatic breast cancer.
    Schwartz J
    Am J Health Syst Pharm; 2009 Dec; 66(23 Suppl 6):S3-8. PubMed ID: 19923317
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Implications of anthracycline-resistant and taxane-resistant metastatic breast cancer and new therapeutic options.
    Rivera E
    Breast J; 2010; 16(3):252-63. PubMed ID: 20408828
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Integrating epothilones into the treatment of patients with metastatic breast cancer: clinical perspectives on incorporating recent data in the practice setting.
    Cigler T; Vahdat L
    Clin Breast Cancer; 2008 Dec; 8 Suppl 4():S166-70. PubMed ID: 19158037
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ixabepilone: a new antimitotic for the treatment of metastatic breast cancer.
    Bhushan S; Walko CM
    Ann Pharmacother; 2008 Sep; 42(9):1252-61. PubMed ID: 18648018
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting the microtubules in breast cancer beyond taxanes: the epothilones.
    Cortes J; Baselga J
    Oncologist; 2007 Mar; 12(3):271-80. PubMed ID: 17405891
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of ixabepilone, a novel epothilone analogue.
    Pivot X; Dufresne A; Villanueva C
    Clin Breast Cancer; 2007 Apr; 7(7):543-9. PubMed ID: 17509162
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacodynamics of tubulin and tubulin-binding agents: extending their potential beyond taxanes.
    Andreopoulou E; Muggia F
    Clin Breast Cancer; 2008 Mar; 8 Suppl 2():S54-60. PubMed ID: 18637400
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.